OR WAIT null SECS
May 24, 2022
AbbVie and Cugene have reached an exclusive license option agreement for CUG252, Cugene’s lead therapeutic candidate.
Sferalp will use Fluid Air’s PolarDry technology for powder processing.
May 23, 2022
AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.
May 16, 2022
Pfizer will acquire Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in migraine treatments, for $11.7 billion.
May 13, 2022
Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.
April 27, 2022
GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.
April 22, 2022
Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.
April 15, 2022
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9 billion.
April 11, 2022
Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.
Pfizer plans to acquire ReViral and its respiratory syncytial virus therapeutic candidates to strengthen Pfizer’s capabilities in infectious disease research.